Systemischer Lupus erythematodes und primäres Sjögren-Syndrom

ZUSAMMENFASSUNG

Die Therapie des systemischen Lupus erythematodes (SLE) und des primären Sjögren-Syndroms (pSS) stellt eine Herausforderung dar. Dies liegt nicht nur an der Heterogenität der Ausprägung beider Erkrankungen, sondern auch an den wenigen erprobten und zugelassenen Therapiemöglichkeiten. Für die Behandlung des SLE zugelassen sind Hydroxychloroquin, Azathioprin, Belimumab und, zur Therapie der schweren Lupus-Nephritis, Cyclophosphamid; durch den gemeinsamen Bundesausschuss wurde zudem Mycophenolat-Mofetil zur Behandlung der Lupus-Nephritis genehmigt, während das bewährte Medikament Methotrexat zwar nicht zugelassen ist, jedoch standardmäßig verwendet wird. Für das pSS gibt es wenige zugelassene Optionen zur Therapie der glandulären Beteiligung. Die Behandlung extraglandulärer, systemischer Manifestationen richtet sich nach dem Organbefall. Hierfür existieren keine zugelassenen Therapieoptionen und wir bewegen uns stets im Off-Label-Bereich. Ziel der vorliegenden Arbeit ist es, die möglichen Therapieoptionen des SLE und pSS zu erläutern und ihren Stellenwert in der Behandlung einzelner Manifestationen darzulegen. Zudem wollen wir dem behandelnden Rheumatologen Hinweise geben, wann ein Off-Label-Use für beide Erkrankungen sinnvoll sein kann.

SUMMARY

The treatment of patients with systemic lupus erythematosus (SLE) and primary Sjögren’s syndrome (pSS) is challenging. This is not only the result of the heterogeneity of manifestations of both diseases but also due to a lack of approved therapeutic options. Approved for the treatment of SLE are hydroxychloroquine, azathioprine, belimumab, and for the treatment of severe lupus nephritis, cyclophosphamide; mycophenolate mofetil can be prescribed for the treatment of lupus nephritis according to the “Gemeinsamer Bundesausschuss”. Methotrexate is not approved for the treatment of SLE but used frequently, nevertheless. Only few approved drugs exist for the treatment of glandular manifestations of pSS. The treatment of extraglandular systemic manifestations depends on the organ involved, however, there are no approved drugs, and we are always treating off-label. It is the aim of this article to outline the therapeutic options for SLE and pSS and their relevance for the treatment of individual manifestations. In addition, we would like to provide the treating rheumatologists with information on when off-label treatment is warranted for both diseases.

Schlüsselwörter

Systemischer Lupus erythematodes - primäres Sjögren-Syndrom - Pharmakotherapie - Immunsuppressiva - Off-Label-Use

Keywords

Systemic lupus erythematosus - primary Sjögren’s syndrome - pharmacotherapy - immunosuppressants - off-label use

Publication History

Article published online:
20 April 2021

• Literatur

• 1 Lee YH, Choi SJ, Ji JD. et al Overall and cause-specific mortality in systemic lupus erythematosus: an updated meta-analysis. Lupus 2016 DOI: 10.1177/0961203315627202
• 2 Bruce IN, O’Keeffe AG, Farewell V. et al Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. Ann Rheum Dis 2013 DOI: 10.1136/annrheumdis-2013-205171
• 3 Frodlund M, Reid S, Wetterö J. et al The majority of Swedish systemic lupus erythematosus patients are still affected by irreversible organ impairment: factors related to damage accrual in two regional cohorts. Lupus 2019 DOI: 10.1177/0961203319860198
• 4 Fanouriakis A, Kostopoulou M, Alunno A. et al 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis 2019 DOI: 10.1136/annrheumdis-2019-215089
• 5 Ramos-Casals M, Brito-Zerón P, Bombardieri S. et al EULAR recommendations for the management of Sjögren’s syndrome with topical and systemic therapies. Ann Rheum Dis 2019 DOI: 10.1136/annrheumdis-2019-216114
• 6 Seror R, Ravaud P, Bowman SJ. et al EULAR Sjogren’s syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren’s syndrome. Ann Rheum Dis 2009 DOI: 10.1136/ard.2009.110619
• 7 Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P. et al Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 2008 DOI: 10.1136/ard.2008.101766
• 8 Pakchotanon R, Gladman DD, Su J. et al More Consistent Antimalarial Intake in First 5 Years of Disease Is Associated with Better Prognosis in Patients with Systemic Lupus Erythematosus. J Rheumatol 2018 DOI: 10.3899/jrheum.170645
• 9 Ruiz-Arruza I, Barbosa C, Ugarte A. et al Comparison of high versus low-medium prednisone doses for the treatment of systemic lupus erythematosus patients with high activity at diagnosis. Autoimmun Rev 2015 DOI: 10.1016/j.autrev.2015.05.011
• 10 Ruiz-Irastorza G, Ugarte A, Saint-Pastou Terrier C. et al Repeated pulses of methyl-prednisolone with reduced doses of prednisone improve the outcome of class III, IV and V lupus nephritis: An observational comparative study of the Lupus-Cruces and lupus-Bordeaux cohorts. Autoimmun Rev 2017 DOI: 10.1016/j.autrev.2017.05.017
• 11 Riemekasten G. Toxizität von Azathioprin. Akt Rheumatol 2008 DOI: 10.1055/s-2008-1027578
• 12 Wong JM, Esdaile JM. Methotrexate in systemic lupus erythematosus. Lupus 2005 DOI: 10.1191/0961203305lu2043rr
• 13 Pego-Reigosa JM, Cobo-Ibáñez T, Calvo-Alén J. et al Efficacy and safety of nonbiologic immunosuppressants in the treatment of nonrenal systemic lupus erythematosus: a systematic review. Arthritis Care Res (Hoboken) 2013 DOI: 10.1002/acr.22035
• 14 Fanouriakis A, Kostopoulou M, Cheema K. et al 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis 2020 DOI: 10.1136/annrheumdis-2020-216924
• 15 Arriens C, Polyakova S, Adzerikho I. et al OP0277 AURORA phase 3 study demonstrates voclosporin statistical superiority over standard of care in lupus nephritis (LN). Ann Rheum Dis 2020 DOI: 10.1136/annrheumdis-2020-eular.5010
• 16 Houssiau FA, Vasconcelos C, D’Cruz D. et al Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis & Rheumatism 2002 DOI: 10.1002/art.10461
• 17 Tamirou F, Husson SN, Gruson D. et al Brief Report: The Euro-Lupus Low-Dose Intravenous Cyclophosphamide Regimen Does Not Impact the Ovarian Reserve, as Measured by Serum Levels of Anti-Müllerian Hormone. Arthritis & rheumatology (Hoboken, N. J.) 2017 DOI: 10.1002/art.40079
• 18 Fava A, Petri M. Systemic lupus erythematosus: Diagnosis and clinical management. J Autoimmun 2018 DOI: 10.1016/j.jaut.2018.11.001
• 19 Urowitz MB, Ohsfeldt RL, Wielage RC. et al Organ damage in patients treated with belimumab versus standard of care: a propensity score-matched comparative analysis. Ann Rheum Dis 2018 DOI: 10.1136/annrheumdis-2018-214043
• 20 Strand V, Levy RA, Cervera R. et al Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials. Ann Rheum Dis 2012 DOI: 10.1136/annrheumdis-2012-202865
• 21 Furie R, Rovin BH, Houssiau F. et al Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis. N Engl J Med 2020 DOI: 10.1056/NEJMoa2001180
• 22 Parodis I, Vital EM, Hassan S-U. et al De novo lupus nephritis during treatment with belimumab. Rheumatology (Oxford) 2020 DOI: 10.1093/rheumatology/keaa796
• 23 Merrill J, Buyon J, Furie R. et al Assessment of flares in lupus patients enrolled in a phase II/III study of rituximab (EXPLORER). Lupus 2011 DOI: 10.1177/0961203310395802
• 24 Rovin BH, Furie R, Latinis K. et al Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 2012 DOI: 10.1002/art.34359
• 25 Reddy V, Klein C, Isenberg DA. et al Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples. Rheumatology (Oxford) DOI: 10.1093/rheumatology/kex067
• 26 Morand EF, Furie R, Tanaka Y. et al Trial of Anifrolumab in Active Systemic Lupus Erythematosus. N Engl J Med 2020 DOI: 10.1056/NEJMoa1912196
• 27 Furie RA, Morand EF, Bruce IN. et al Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial. The Lancet Rheumatology 2019 DOI: 10.1016/S2665-9913(19)30076-1
• 28 Salmon JE, Niewold TB. A Successful Trial for Lupus – How Good Is Good Enough?. N Engl J Med 2020 DOI: 10.1056/NEJMe1915490
• 29 Gottenberg J-E, Ravaud P, Puéchal X. et al Effects of hydroxychloroquine on symptomatic improvement in primary Sjögren syndrome: the JOQUER randomized clinical trial. JAMA 2014 DOI: 10.1001/jama.2014.7682
• 30 Lee AS, Scofield RH, Hammitt KM. et al Consensus Guidelines for Evaluation and Management of Pulmonary Disease in Sjögren’s. Chest 2020 DOI: 10.1016/j.chest.2020.10.011
• 31 François H, Mariette X. Renal involvement in primary Sjögren syndrome. Nat Rev Nephrol 2015 DOI: 10.1038/nrneph.2015.174
• 32 Goules AV, Tatouli IP, Moutsopoulos HM. et al Clinically significant renal involvement in primary Sjögren’s syndrome: clinical presentation and outcome. Arthritis & Rheumatism 2013 DOI: 10.1002/art.38100
• 33 Seeliger T, Prenzler NK, Gingele S. et al Neuro-Sjögren: Peripheral Neuropathy With Limb Weakness in Sjögren’s Syndrome. Front Immunol 2019 DOI: 10.3389/fimmu.2019.01600
• 34 Tobin WO, Weinshenker BG, Lucchinetti CF. Longitudinally extensive transverse myelitis. Curr Opin Neurol 2014 DOI: 10.1097/WCO.0000000000000093
• 35 van der Heijden EHM, Blokland SLM, Hillen MR. et al Leflunomide-hydroxychloroquine combination therapy in patients with primary Sjögren’s syndrome (RepurpSS-I): a placebo-controlled, double-blinded, randomised clinical trial. The Lancet Rheumatology 2020 DOI: 10.1016/S2665-9913(20)30057-6
• 36 van Nimwegen JF, Mossel E, van Zuiden GS. et al Abatacept treatment for patients with early active primary Sjögren’s syndrome: a single-centre, randomised, double-blind, placebo-controlled, phase 3 trial (ASAP-III study). The Lancet Rheumatology 2020 DOI: 10.1016/S2665-9913(19)30160-2
• 37 Fisher BA, Szanto A, Ng W-F. et al Assessment of the anti-CD40 antibody iscalimab in patients with primary Sjögren’s syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study. The Lancet Rheumatology 2020 DOI: 10.1016/S2665-9913(19)30135-3
• 38 Dörner T, Posch MG, Li Y. et al Treatment of primary Sjögren’s syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity. Ann Rheum Dis 2018 DOI: 10.1136/annrheumdis-2018-214720
• 39 Kraaij T, Kamerling SWA, Rooij ENM de. et al The NET-effect of combining rituximab with belimumab in severe systemic lupus erythematosus. J Autoimmun 2018 DOI: 10.1016/j.jaut.2018.03.003